Skip to main content
SpringerLink
Log in

The Pharmacology of the Hypouricemic Effect of Benzbromarone

  • Chapter
Purine Metabolism in Man—II

Part of the book series: Advances in Experimental Medicine and Biology ((AEMB,volume 76B))

Abstract

The pharmacological reduction of the serum uric acid in man has been commonly achieved by the use of compounds which increase the renal excretion of uric acid. Although numerous uricosuric drugs have been available, sulfinpyrazone and probenecid have gained the widest usage. Recently a new class of uricosuric compounds, the benzofurans, has been discovered and tested. One of these compounds, benzbromarone, has been found useful in the clinical management of hyperuricemia (for bibliography see 1). In addition to its uricosuric properties it has been proposed that the hypouricemic effects of benzbromarone may also result from the inhibition of uric acid synthesis. We have evaluated the mechanism by which benzbromarone could lower the serum uric acid in man (1).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Sinclair, D.S. and Fox, I.H. 1975. The Pharmacology of hypouricemic effect of benzbromarone. J. Rheumat. 2: 437–445.

    CAS  Google Scholar 

  2. Begemann, H. and I. Neu. 1975. Die behandlung der urikopathie met benzbromaronum unter besonderer berucksichtigung der neireninsuffizienz. Therapiewoche 25:2184–2194.

    Google Scholar 

  3. Muller, M.M., Fuchs, H., Pischek, G. and Bresnik, W. 1975. Purinstoffwechsel und harnsaurepool bei gichtpatienten unter benzbromaronthérapie. Therapiewoche 25:514–521.

    Google Scholar 

  4. Sorensen, L.B. and Levison, D.J. 1976. Clinical evaluation of benzbromarone. Arthritis Rheumat. 19:183–190.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Purine Research Laboratory, Rheumatic Disease Unit, Wellesley Hospital, University of Toronto, Toronto, Canada

    Irving H. Fox & David S. Sinclair

Authors
  1. Irving H. Fox
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David S. Sinclair
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. University of Vienna, Vienna, Austria

    Mathias M. Müller  & Erich Kaiser  & 

  2. University of California, San Diego, La Jolla, California, USA

    J. Edwin Seegmiller

Rights and permissions

Reprints and permissions

Copyright information

© 1977 Plenum Press, New York

About this chapter

Cite this chapter

Fox, I.H., Sinclair, D.S. (1977). The Pharmacology of the Hypouricemic Effect of Benzbromarone. In: Müller, M.M., Kaiser, E., Seegmiller, J.E. (eds) Purine Metabolism in Man—II. Advances in Experimental Medicine and Biology, vol 76B. Springer, Boston, MA. https://doi.org/10.1007/978-1-4684-3285-5_49

Download citation

  • DOI: https://doi.org/10.1007/978-1-4684-3285-5_49

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4684-3287-9

  • Online ISBN: 978-1-4684-3285-5

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation